Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of NuVasive
So what: Color me unsurprised. While the beginning of the press release is long on hyperbole -- calling it a "strategic foray" into an $800 million market -- the announcement closes with the sad news that the deal will be immediately dilutive ($40 million of the purchase price will be paid in stock) yet won't offer any earnings upside before 2012.
Now what: To be fair, NuVasive is making a longer-term bet on the need for less-invasive spinal surgery, and Impulse Monitoring's technology could induce doctors to try the company's products. Meanwhile, Intuitive Surgical
Interested in more info on NuVasive? Add it to your watchlist by clicking here.